New drug combo may boost surgery success in returning liver cancer
NCT ID NCT07644208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug (PD-1/IL-2 bispecific antibody) given before a second surgery in 30 adults whose liver cancer returned early after initial curative surgery. The goal is to see if the drug can shrink or kill more cancer cells before the operation, potentially improving long-term outcomes. Participants receive the drug for 3 cycles, then undergo surgery if scans show the tumor is removable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?